Article
Author(s):
Approximately half of patients who received a high dose of the stem cells had reduced symptoms.
Findings from a recent study suggests that stem cells from umbilical cord blood could be a potentially effective treatment for moderate-to-severe eczema or atopic dermatitis.
The study, published by STEM CELLS, included 32 patients who either received low doses or high doses of the stem cells subcutaneously.
Researchers found that at 12 weeks, 55% of patients receiving a high dose had a reduced Eczema Area and Severity Index score.
Patients receiving a high dose of the stem cells had a significantly reduced rate of immune-related markers of atopic dermatitis, according to the study.
"This study is a first-in-class study demonstrating that adults with moderate-to-severe atopic dermatitis responded to a treatment of stem cells derived from umbilical cord blood," concluded study senior author Tae-Yoon Kim, PhD. "The single treatment of stem cells in patients resulted in the significant and persistent improvement in disease symptoms throughout the follow-up period of 12 weeks."
FDA Approves DFD-29 for Treatment of Adults With Rosacea-Related Inflammatory Lesions